A special committee of Genentech Inc."s board rejected Roche Holding AG"s hostile $86.50 offer for the remaining portion of the biotechnology company, unanimously urging shareholders to reject the bid. In a letter to the shareholders, the committee of Genentech said that Roche"s offer of $86.50 a share substantially undervalued the company.